Current Infectious Disease Reports

, Volume 15, Issue 1, pp 52–60

HCV Enters the Twenty-First Century

HIV/AIDS (R MacArthur, Section Editor)

DOI: 10.1007/s11908-012-0313-1

Cite this article as:
Brar, I., Baxa, D. & Markowitz, N. Curr Infect Dis Rep (2013) 15: 52. doi:10.1007/s11908-012-0313-1
  • 224 Downloads

Abstract

Almost one-third of Americans infected with human immunodeficiency virus (HIV) and 7 million worldwide are coinfected with hepatitis C virus (HCV). The principal route of HCV spread in the US is injection drug use but there are recent reports of outbreaks of acute HCV infection among HIV-infected men who have sex with men. With increased survival as a result of highly active antiretroviral therapy, HCV-associated liver disease has become a leading cause of death in HIV-infected individuals. Currently, telaprevir and boceprevir, both NS3/NS4A inhibitors that significantly improve sustained response when added to pegylated interferon and ribavirin, are approved only for HCV monoinfection. The optimal combination of agents, therapy durations and the timing of treatment remain major challenges in coinfected patients.

Keywords

HIVHCVCoinfectionBoceprevirTelaprevir

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  1. 1.Henry Ford Hospital, Division of Infectious DiseasesDetroitUSA